Vedanta opens manufacturing facility to produce lead candidate as it heads for PhIII

The microbiome startup Vedanta, while still forging ahead with the Phase III process for its Clostridioides difficile infection candidate, has completed a manufacturing facility to produce the drug.

Vedanta’s new 7,000-square-foot facilities in Cambridge, MA, are designed to manufacture clinical and commercial supplies for its portfolio, including their oral c. difficile candidate VE303.

The facility is an extension of the company’s existing manufacturing capabilities and can produce multiple drug candidates, according to Vedanta. It also has CGMP capabilities to handle everything from clinical development to commercial launch. Manufacturing is expected to kick off in Q4 of this year.

The cost of the facility and employment details were not disclosed to Endpoints News, however, Vedanta did confirm in an email that government funds were given to the company. The company is a funded contractor of BARDA and support went to Vedanta’s lead program and select aspects of the facility design and commissioning,…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*